科研动态期刊摘要

急性冠脉综合征中普拉格雷与替格瑞洛的比较

NEJM · 2026-11-12

完整摘要 · 中文译文

背景:对于急性冠脉综合征患者,普拉格雷或替格瑞洛是否应作为首选的P2Y12抑制剂尚不确定。 方法:我们在瑞典开展了一项基于注册登记、开放标签、阶梯楔形、整群随机试验,纳入因急性冠脉综合征接受经皮冠状动脉介入治疗的成人患者。七个地区分为三个集群,在2021年至2024年间的四个9个月期间内,按随机顺序从替格瑞洛转换为普拉格雷作为默认的P2Y12抑制剂。主要终点为截至1年的全因死亡、致死性或非致死性心肌梗死或致死性或非致死性卒中的复合终点,数据从国家注册登记中确定。在意向性治疗分析中,使用针对集群和日历时间校正的混合模型获得政策层面的估计值。 结果:共纳入17,095例患者;9444例在默认替格瑞洛策略下接受治疗,7651例在默认普拉格雷策略下接受治疗。患者平均(±SD)年龄为69.8±11.5岁,36.8%的患者至少75岁;27.8%的患者为女性。共有39.4%表现为ST段抬高型心肌梗死(STEMI),43.7%为非ST段抬高型心肌梗死,16.8%为不稳定型心绞痛。1年时,替格瑞洛策略组有11.8%的患者发生主要终点事件,普拉格雷策略组为11.1%(校正比值比[普拉格雷 vs. 替格瑞洛],0.90;95%置信区间[CI],0.77至1.06),大出血分别发生于4.4%和4.2%的患者(校正比值比,0.80;95% CI,0.64至0.99)。 结论:在接受经皮冠状动脉介入治疗的未选择急性冠脉综合征患者人群中,默认普拉格雷策略下的缺血事件风险并未低于默认替格瑞洛策略。(由Region Västra Götaland资助;SWITCH-SWEDEHEART ClinicalTrials.gov注册号,NCT05183178。)

完整摘要 · 英文原文

BACKGROUND: Whether prasugrel or ticagrelor should be the preferred P2Y12 inhibitor for patients with an acute coronary syndrome is uncertain. METHODS: We conducted a registry-based, open-label, stepped-wedge, cluster-randomized trial in Sweden involving adults who had undergone percutaneous coronary intervention for an acute coronary syndrome. Seven regions, grouped into three clusters, switched from ticagrelor to prasugrel as the default P2Y12 inhibitor in a randomized sequence across four 9-month periods between 2021 and 2024. The primary end point was a composite of death from any cause, fatal or nonfatal myocardial infarction, or fatal or nonfatal stroke through 1 year, as ascertained from national registries. In the intention-to-treat analysis, a mixed model adjusted for cluster and calendar time was used to obtain a policy-level estimate. RESULTS: A total of 17,095 patients were enrolled; 9444 received care under the default ticagrelor policy, and 7651 received care under the default prasugrel policy. The mean (±SD) age of the patients was 69.8±11.5 years, and 36.8% were at least 75 years old; 27.8% of the patients were female. A total of 39.4% presented with ST-segment elevation myocardial infarction (STEMI), 43.7% with non-STEMI, and 16.8% with unstable angina. At 1 year, a primary end-point event had occurred in 11.8% of the patients in the ticagrelor-policy group and in 11.1% of those in the prasugrel-policy group (adjusted odds ratio [prasugrel vs. ticagrelor], 0.90; 95% confidence interval [CI], 0.77 to 1.06), and major bleeding had occurred in 4.4% and 4.2%, respectively (adjusted odds ratio, 0.80; 95% CI, 0.64 to 0.99). CONCLUSIONS: In an unselected population of patients with an acute coronary syndrome who had undergone percutaneous coronary intervention, the risk of ischemic events was not lower with a default prasugrel policy than with a default ticagrelor policy. (Funded by Region Västra Götaland; SWITCH-SWEDEHEART ClinicalTrials.gov number, NCT05183178.).

English
Prasugrel versus Ticagrelor in Acute Coronary Syndromes
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界